NewEdge Advisors’s Novavax NVAX Stock Holding History

NewEdge Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500	Closed	-$6.33K	–	3902
2024 Q2	$6.33K	Hold	500	–	–	﹤0.01%	3014
2024 Q1	$2.39K	Hold	500	–	–	﹤0.01%	3332
2023 Q4	$2.4K	Hold	500	–	–	﹤0.01%	3306
2023 Q3	$3.62K	Hold	500	–	–	﹤0.01%	2896
2023 Q2	$3.71K	Sell	500 -60	-11%	-$472	﹤0.01%	2906
2023 Q1	$3.88K	Hold	560	–	–	﹤0.01%	2858
2022 Q4	$6	Buy	+560	New	+$9.88K	﹤0.01%	3783
2022 Q3	–	Sell	-10,161	Closed	-$523K	–	1620
2022 Q2	$523K	Buy	+10,161	New	+$526K	0.01%	960
2022 Q1	–	Sell	-2,697	Closed	-$386K	–	1469
2021 Q4	$386K	Sell	2,697 -2,611	-49%	-$449K	0.01%	1200
2021 Q3	$1.1M	Buy	+5,308	New	+$1.17M	0.03%	496

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

NewEdge Advisors's NVAX Position: Q3 2024 in Review

NewEdge Advisors sold out of Novavax (NVAX) in Q3 2024, closing a stake of 500 shares — an estimated $6.33K sold.

NewEdge Advisors first reported a position in NVAX in Q3 2021 and held it in 10 quarters. The position peaked at $1.1M in Q3 2021. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

NewEdge Advisors reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
NewEdge Advisors sold 500 Novavax shares in Q3 2024, an estimated $6.33K.
NewEdge Advisors first reported a position in Novavax in Q3 2021 and held it in 10 quarters.
NewEdge Advisors's Novavax position peaked at $1.1M in Q3 2021.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.